Tin tức & Cập nhật

A 5-year analysis of the phase III ALLEGRO-LT study, presented at EADV 2026, shows that patients with the least baseline scalp hair loss respond best and fastest to the Janus kinase (JAK) inhibitor ritlecitinib.

Replacing two cycles of highly toxic, high-dose combination chemotherapy with two cycles of blinatumomab as first-line (1L) treatment significantly improves outcomes including 4-year event-free survival (EFS) and reduces adverse events (AEs) in paediatric patients with high-risk B-cell acute lymphoblastic leukaemia (B-ALL), results of the phase III AIEOP-BFM 2017 trial have shown.

New drug applications approved by US FDA as of 16-30 September 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Cytological analysis of voided urine and vaginal fluid has good accuracy for detecting endometrial cancer in women with postmenopausal bleeding, as shown in the DETECT trial.

Systemic sclerosis (SSc) patients with positive anti-RNA polymerase III (ARA) prior to autologous haematopoietic cell transplantation (HCT) show a reduced risk of relapse, reveals a study. Moreover, no association has been observed between post-HCT autoantibodies and relapse risk.

A combined intrahepatic (IH) and periduodenal (PD) embolization strategy results in higher initial response rates and longer duration of remission compared with IH embolization alone in congenital heart disease (CHD) patients with protein-losing enteropathy (PLE), a study has shown.

An association exists between daily glucocorticoid (GC) dose and worse patient-reported outcomes (PROs) in patients with systemic lupus erythematosus (SLE) who have achieved Lupus Low Disease Activity State (LLDAS), even after adjustments for potential confounders, according to a study.

Use of aspirin after curative-intent treatment of colorectal cancer (CRC) liver metastases does not appear to improve disease-free survival and is even associated with reduced overall survival and more serious adverse events (AEs), according to the phase III ASAC trial